<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917160</url>
  </required_header>
  <id_info>
    <org_study_id>DO608427A</org_study_id>
    <nct_id>NCT03917160</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Effect of Abdominal EMS (Electrical Muscle Stimulation) on AWR (Abdominal Wall Restoration) in Post - Partum Women</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate the Effect of Abdominal EMS (Electrical Muscle Stimulation) on AWR (Abdominal Wall Restoration) in Post - Partum Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of Abdominal EMS
      (Electrical Muscle Stimulation) on AWR (Abdominal Wall Restoration) in Post - Partum Women
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">March 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inter-recti distance (IRD), measured via Magnetic Resonance Imaging.</measure>
    <time_frame>1 month</time_frame>
    <description>Up to 5 subjects will undergo MRI to evaluate effect of the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inter-recti distance (IRD), measured via UltraSound Imaging to evaluate effect of the treatment</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Urogynecological Complaints measured using the Pelvic Floor Distress Inventory.</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Pelvic Floor Distress Inventory - The PFDI-20 is both a symptom inventory and a measure of the degree of bother and distress (quality-of-life) caused by pelvic floor symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Lumbopelvic and/or Abdominal Pain measured by Visual Analog Scale.</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Pain will be assessed based on the Numerical Scale Response (NSR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator satisfaction</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Satisfaction assessment will be performed by the study investigator using using 0 - 4 -points Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject improvement and satisfaction</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Improvement and satisfaction assessment will be performed independently by the subject using 0 - 4 -points Likert scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Abdominal Wall Restoration</condition>
  <condition>Diastasis Recti</condition>
  <arm_group>
    <arm_group_label>EMS treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo treatment with EMS and measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will undergo measurements only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMS device</intervention_name>
    <description>EMS treatment will be performed</description>
    <arm_group_label>EMS treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Post-partum women aged 18-45 years with symptoms of diastasis recti and weakness of
             the linea alba

          -  Informed Consent Form signed by the subject.

          -  BMI interval: 18.5 ≤ BMI ≤ 32 (normal to overweight, but not obese).

          -  Willing to follow the treatment and follow-up schedule and post-treatment care
             instructions.

          -  Willing to have photographs and images taken of the treated areas to be used
             de-identified in evaluations, publications and presentations.

          -  In addition, negative urine pregnancy test as tested before each treatment and at the
             last visit for women with childbearing potential (e.g. not menopause).

        Exclusion Criteria:

          -  - Unable to commit to future appointments

          -  Planning on moving away from the local area within 6 months

          -  History of other energy-based therapy within one year

          -  Diffuse pain syndrome or chronic pain requiring daily narcotics

          -  Active electrical implant/device in any region of the body, including pacemaker or
             internal defibrillator

          -  Permanent implant in the treated area such as metal plates, screws or silicon, metal
             piercing or other.

          -  Current or history of skin cancer, or current condition of any other type of cancer,
             or pre-malignant moles.

          -  Severe concurrent conditions, such as cardiac disorders, sensory disturbances,
             epilepsy, uncontrolled hypertension, and liver or kidney diseases.

          -  History of skin disorders, keloids, abnormal wound healing, as well as very dry and
             fragile skin.

          -  History of bleeding coagulopathies or use of anticoagulants except for low-dose
             aspirin.

          -  Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex
             in the treatment area, may be treated only following a prophylactic regimen.

          -  Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use
             of immunosuppressive medications.

          -  Pregnancy.

          -  Poorly controlled endocrine disorders, such as Diabetes, or thyroid dysfunction and
             hormonal virilization.

          -  Isotretinoin (Accutane) within last 6 months.

          -  Any active condition in the treatment area, such as sores, Psoriasis, eczema, and
             rash, open lacerations, abrasions or lesions, infection in the area to be treated,
             current urinary tract infection or pelvic infection, uterine prolapse, cystocele,
             rectocele.

          -  Any surgical procedure in the treatment area within the last 12 months or before
             complete healing.

          -  Having received treatment with light, laser, RF, or other devices in the treated area
             within 2-3 weeks for non-ablative procedures, and 6-12 weeks for ablative fractional
             laser resurfacing (according to treatment severity) prior to treatment, except special
             recommendations.

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing
             agents) one week before and after each treatment session, as per the practitioner's
             discretion.

          -  As per the practitioner's discretion, refrain from treating any condition which might
             make it unsafe for the patient.

          -  Any therapies or medications which may interfere with the use of the study device.

          -  Compromised health as determined by the study doctor.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postpartum women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri Ramirez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Oklahoma Women's Health 731 12th Ave NW Suite 201 Ardmore, OK 73401</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Abdulla</last_name>
    <phone>+1.949.305.0106</phone>
    <email>maureena@inmodemd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Oklahoma Women's Health</name>
      <address>
        <city>Ardmore</city>
        <state>Oklahoma</state>
        <zip>73401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cari</last_name>
      <phone>580-224-9000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

